Sialic acids: An Avenue to Target Cancer Progression, Metastasis, and Resistance to Therapy

[1] Ghosh, S. ‘Sialic Acid and Biology of Life: An Introduction’, Sialic Acids and Sialoglycoconjugates in the Biology of Life, Health and Disease 2020, pp. 1–61. GhoshS ‘Sialic Acid and Biology of Life: An Introduction’ Sialic Acids and Sialoglycoconjugates in the Biology of Life, Health and Disease 2020 1 61 10.1016/B978-0-12-816126-5.00001-9 Search in Google Scholar

[2] Varki, A. ‘Biological Roles of Glycans’, Glycobiology, vol. 27, 2017, pp. 3–49. VarkiA ‘Biological Roles of Glycans’ Glycobiology 27 2017 3 49 10.1093/glycob/cww086588443627558841 Search in Google Scholar

[3] Li, Y and Chen, X. ‘Sialic Acid Metabolism and Sialyltransferases: Natural Functions and Applications’, Applied Microbiology and Biotechnology; vol. 94, no. 4, 2012, pp. 887–905. LiY ChenX ‘Sialic Acid Metabolism and Sialyltransferases: Natural Functions and Applications’ Applied Microbiology and Biotechnology 94 4 2012 887 905 10.1007/s00253-012-4040-1353497422526796 Search in Google Scholar

[4] Zhou, X, Yang, G, Guan, F. ‘Biological Functions and Analytical Strategies of Sialic Acids in Tumor’, Cells, 9, 2020, p. 273. ZhouX YangG GuanF ‘Biological Functions and Analytical Strategies of Sialic Acids in Tumor’ Cells 9 2020 273 10.3390/cells9020273707269931979120 Search in Google Scholar

[5] Zhang, Z, Wuhrer, M and Holst, S. ‘Serum Sialylation Changes in Cancer’ Glycoconjugate Journal, vol. 35, 2018, pp. 139–160. ZhangZ WuhrerM HolstS ‘Serum Sialylation Changes in Cancer’ Glycoconjugate Journal 35 2018 139 160 10.1007/s10719-018-9820-0591698529680984 Search in Google Scholar

[6] Rodrigues, E and Macauley, MS. ‘Hypersialylation in cancer: Modulation of Inflammation and Therapeutic Opportunities’, Cancers, vol. 10,, no. 6, 2018, p. 207. RodriguesE MacauleyMS ‘Hypersialylation in cancer: Modulation of Inflammation and Therapeutic Opportunities’ Cancers 10 6 2018 207 10.3390/cancers10060207602536129912148 Search in Google Scholar

[7] Büll, C, Stoel, MA, Den Brok, MH and Adema, GJ. ‘Sialic Acids Sweeten a Tumor’s Life’, Cancer Res, vol. 74, no. 12, 2014, pp. 3,199–3,204. BüllC StoelMA Den BrokMH AdemaGJ ‘Sialic Acids Sweeten a Tumor’s Life’ Cancer Res 74 12 2014 3,199 3,204 10.1158/0008-5472.CAN-14-072824830719 Search in Google Scholar

[8] Teoh, ST, Ogrodzinski, MP, Ross, C, Hunter, KW, Lunt, SY. ‘Sialic Acid Metabolism: A Key Player in Breast Cancer Metastasis Revealed by Metabolomics’, Front. Oncol, vol. 8, 2018, p 174. TeohST OgrodzinskiMP RossC HunterKW LuntSY ‘Sialic Acid Metabolism: A Key Player in Breast Cancer Metastasis Revealed by Metabolomics’ Front. Oncol 8 2018 174 10.3389/fonc.2018.00174598544929892572 Search in Google Scholar

[9] Ugorski, M, Laskowska, A. Sialyl, Lewis a, ‘A Tumor-Associated Carbohydrate Antigen In-Volved in Adhesion and Metastatic Potential of Cancer Cells. Acta Biochemica Plonica’, vol. 49, no 2, 2002 pp. 303–311. UgorskiM LaskowskaA Sialyl, Lewis a, ‘A Tumor-Associated Carbohydrate Antigen In-Volved in Adhesion and Metastatic Potential of Cancer Cells Acta Biochemica Plonica’ 49 2 2002 303 311 10.18388/abp.2002_3788 Search in Google Scholar

[10] Seales, EC, Jurado, GA, Singhal, A, Bellis, SL. ‘Ras Oncogene Directs Expression of a Differentially Sialylated, Functionally Altered β1 Integrin’, Oncogene, vol. 22, no. 46, 2003, pp. pp. 7,137–7,145. SealesEC JuradoGA SinghalA BellisSL ‘Ras Oncogene Directs Expression of a Differentially Sialylated, Functionally Altered β1 Integrin’ Oncogene 22 46 2003 7,137 7,145 10.1038/sj.onc.120683414562042 Search in Google Scholar

[11] Sakuma, K, Aoki, M, Kannagi, R. ‘Transcription Factors C-Myc and CDX2 Mediate E-Selectin Ligand Expression in Colon Cancer Cells Undergoing EGF/Bfgf-Induced Epithelial-Mesenchymal Transition’, Proc. Natl. Acad. Sci. U.S.A, vol. 109, no. 20, pp., pp. 7,776–7,781. SakumaK AokiM KannagiR ‘Transcription Factors C-Myc and CDX2 Mediate E-Selectin Ligand Expression in Colon Cancer Cells Undergoing EGF/Bfgf-Induced Epithelial-Mesenchymal Transition’ Proc. Natl. Acad. Sci. U.S.A 109 20 7,776 7,781 10.1073/pnas.1111135109335667822547830 Search in Google Scholar

[12] Almaraz, RT, Tian, Y, Bhattarcharya, R, et al. ‘Metabolic Flux Increases Glycoprotein Sialylation: Implications for Cell Adhesion and Cancer Metastasis’, Mol. Cell. Proteomics, vol. 11, no. 7, 2012, M112.017558. AlmarazRT TianY BhattarcharyaR ‘Metabolic Flux Increases Glycoprotein Sialylation: Implications for Cell Adhesion and Cancer Metastasis’ Mol. Cell. Proteomics 11 7 2012 M112.017558. 10.1074/mcp.M112.017558339495922457533 Search in Google Scholar

[13] Miyagi, T, Takahashi, K, Hata, K, Shiozaki, K, Yamaguchi, K. ‘Sialidase Significance for Cancer Progression’, Glycoconj. J, vol. 29, 2012, pp. 567–577. MiyagiT TakahashiK HataK ShiozakiK YamaguchiK ‘Sialidase Significance for Cancer Progression’ Glycoconj. J 29 2012 567 577 10.1007/s10719-012-9394-122644327 Search in Google Scholar

[14] Büll, C, den Brok, MH, Adema, GJ. ‘Sweet Escape: Sialic Acids in Tumor Immune Evasion’, Biochim. Biophys. Acta, vol 1,846, no. 1, 2014, pp. 238–246. BüllC den BrokMH AdemaGJ ‘Sweet Escape: Sialic Acids in Tumor Immune Evasion’ Biochim. Biophys. Acta 1,846 1 2014 238 246 10.1016/j.bbcan.2014.07.00525026312 Search in Google Scholar

[15] Varki, A, Gagneux, P. ‘Multifarious Roles of Sialic Acids in Immunity’,. Ann. N. Y. Acad. Sci, vol. 1253, no. 1., 2012 pp. 16–36. VarkiA GagneuxP ‘Multifarious Roles of Sialic Acids in Immunity’ Ann. N. Y. Acad. Sci 1253 1 2012 16 36 10.1111/j.1749-6632.2012.06517.x335731622524423 Search in Google Scholar

[16] Ferreira, VP, Pangburn, MK, Cortés, C. ‘Complement Control Protein Factor H: The Good, the Bad, and the Inadequate’ Molecular Immunology, vol. 47, no. 13, pp. 2,187–2,197. FerreiraVP PangburnMK CortésC ‘Complement Control Protein Factor H: The Good, the Bad, and the Inadequate’ Molecular Immunology 47 13 2,187 2,197 10.1016/j.molimm.2010.05.007292195720580090 Search in Google Scholar

[17] Gancz, D, Fishelson, Z. ‘Cancer Resistance to Complement-Dependent Cytotoxicity (CDC): Problem-Oriented Research and Development’, Molecular Immunology, vol. 46, no. 14, 2009, pp. 2,794–2,800. GanczD FishelsonZ ‘Cancer Resistance to Complement-Dependent Cytotoxicity (CDC): Problem-Oriented Research and Development’ Molecular Immunology 46 14 2009 2,794 2,800 10.1016/j.molimm.2009.05.00919501402 Search in Google Scholar

[18] Pio, R, Ajona, D, Lambris, JD. ‘Complement Inhibition in Cancer Therapy’, Seminars in Immunology, vol. 25, no. 1, pp. 54–64. PioR AjonaD LambrisJD ‘Complement Inhibition in Cancer Therapy’ Seminars in Immunology 25 1 54 64 10.1016/j.smim.2013.04.001373308523706991 Search in Google Scholar

[19] Cheng, M, Chen, Y, Xiao, W, Sun, R, Tian, Z. ‘NK Cell-Based Immunotherapy for Malignant Diseases, Cellular and Molecular Immunology, vol. 10,, no. 3, 2013pp. 230–252. ChengM ChenY XiaoW SunR TianZ ‘NK Cell-Based Immunotherapy for Malignant Diseases Cellular and Molecular Immunology 10 3 2013 230 252 10.1038/cmi.2013.10407673823604045 Search in Google Scholar

[20] Cohen, M. et al., ‘’Sialylation of 3-Methylcholanthrene–Induced Fibrosarcoma Determines Antitumor Immune Responses during Immunoediting’, J. Immunol, vol. 185, no. 10, 2010, pp. 5,869–5,878. CohenM ‘’Sialylation of 3-Methylcholanthrene–Induced Fibrosarcoma Determines Antitumor Immune Responses during Immunoediting’ J. Immunol 185 10 2010 5,869 5,878 10.4049/jimmunol.100163520956342 Search in Google Scholar

[21] Jandus, C. et al. ‘Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance’, J. Clin. Invest, vol. 124, no. 4, 2014, \ pp. 1,810–1,820. JandusC ‘Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance’ J. Clin. Invest 124 4 2014 1,810 1,820 10.1172/JCI65899397307324569453 Search in Google Scholar

[22] Daly, J, Carlsten, M, O’Dwyer, M. ‘Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer’, Front. Immunol, vol. 10, 2019, p. 1,047. DalyJ CarlstenM O’DwyerM ‘Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer’ Front. Immunol 10 2019 1,047 10.3389/fimmu.2019.01047652179731143186 Search in Google Scholar

[23] Park, JE. et al. ‘Fine Specificity of Natural Killer T Cells Against GD3 Ganglioside and Identification of GM3 As an Inhibitory Natural Killer T-Cell Ligand’, Immunology, vol. 123, no. 1, 2008, pp. 145–155. ParkJE ‘Fine Specificity of Natural Killer T Cells Against GD3 Ganglioside and Identification of GM3 As an Inhibitory Natural Killer T-Cell Ligand’ Immunology 123 1 2008 145 155 10.1111/j.1365-2567.2007.02760.x243327318154620 Search in Google Scholar

[24] Wondimu, A, Liu, Y, Ma JS, Radoja S, Ladisch S. ‘Ganglioside Inhibition of CD8 + T Cell Cytotoxicity: Interference with Lytic Granule Trafficking and Exocytosis’, J. Immunol, vol. 189, no. 7, 2012, pp. 3,521–3,527. WondimuA LiuY MaJS RadojaS LadischS ‘Ganglioside Inhibition of CD8 + T Cell Cytotoxicity: Interference with Lytic Granule Trafficking and Exocytosis’ J. Immunol 189 7 2012 3,521 3,527 10.4049/jimmunol.120125622956583 Search in Google Scholar

[25] Li, F, Ding, J. ‘Sialylation Is Involved in Cell Fate Decision During Development, Reprogramming and Cancer Progression’, Protein and Cell, vol. 10, no. 8, 2018, pp 550–565. LiF DingJ ‘Sialylation Is Involved in Cell Fate Decision During Development, Reprogramming and Cancer Progression’ Protein and Cell 10 8 2018 550 565 10.1007/s13238-018-0597-5662659530478534 Search in Google Scholar

[26] Asano, K. et al. ‘CD169-Positive Macrophages Dominate Antitumor Immunity by Crosspresenting Dead Cell-Associated Antigens’, Immunity, vol. 34, no. 1, 2011; pp. 85–95. AsanoK ‘CD169-Positive Macrophages Dominate Antitumor Immunity by Crosspresenting Dead Cell-Associated Antigens’ Immunity 34 1 2011 85 95 10.1016/j.immuni.2010.12.01121194983 Search in Google Scholar

[27] Jales, A. et al., ‘Ganglioside-Exposed Dendritic Cells Inhibit T-Cell Effector Function by Promoting Regulatory Cell Activity’, Immunology, vol. 132, no. 1, 2011, pp. 134–143. JalesA ‘Ganglioside-Exposed Dendritic Cells Inhibit T-Cell Effector Function by Promoting Regulatory Cell Activity’ Immunology 132 1 2011 134 143 10.1111/j.1365-2567.2010.03348.x301508320875076 Search in Google Scholar

[28] Munkley, J, Scott, E., ‘Targeting Aberrant Sialylation to Treat Cancer’, Medicines, vol. 6, no. 4, 2019 p. 102. MunkleyJ ScottE. ‘Targeting Aberrant Sialylation to Treat Cancer’ Medicines 6 4 2019 102 10.3390/medicines6040102696394331614918 Search in Google Scholar

[29] Shen, L. et al., ‘Enhanced Expression of α2,3-Linked Sialic Acids Promotes Gastric Cancer Cell Metastasis and Correlates with Poor Prognosis’, Int. J. Oncol, vol. 50, no. 4, 2017 pp. 1,201–1,210. ShenL ‘Enhanced Expression of α2,3-Linked Sialic Acids Promotes Gastric Cancer Cell Metastasis and Correlates with Poor Prognosis’ Int. J. Oncol 50 4 2017 1,201 1,210 10.3892/ijo.2017.388228259967 Search in Google Scholar

[30] Van Slambrouck, S. et al., ‘Carbohydrate-to-Carbohydrate Interactions Between α2,3-Linked Sialic Acids on α2 Integrin Subunits and Asialo-GM1 Underlie the Bone Metastatic Behaviour of LNCAP-Derivative C4-2B Prostate Cancer Cells’, Biosci. Rep, vol. 34, no. 5, 2014 pp. 546–557. Van SlambrouckS ‘Carbohydrate-to-Carbohydrate Interactions Between α2,3-Linked Sialic Acids on α2 Integrin Subunits and Asialo-GM1 Underlie the Bone Metastatic Behaviour of LNCAP-Derivative C4-2B Prostate Cancer Cells’ Biosci. Rep 34 5 2014 546 557 10.1042/BSR20140096416612025137483 Search in Google Scholar

[31] Yuan, Q. et al., ‘Modification of α2,6-Sialylation Mediates the Invasiveness and Tumorigenicity of Non-Small Cell Lung Cancer Cells In Vitro and In Vivo Via Notch1/Hes1/MMPs Pathway’, Int. J. Cancer, vol. 143, no. 9, 2018, pp. 1–27. YuanQ ‘Modification of α2,6-Sialylation Mediates the Invasiveness and Tumorigenicity of Non-Small Cell Lung Cancer Cells In Vitro and In Vivo Via Notch1/Hes1/MMPs Pathway’ Int. J. Cancer 143 9 2018 1 27 10.1002/ijc.3173729981167 Search in Google Scholar

[32] Lu J., et al., ‘β-Galactoside α2,6-Sialyltranferase 1 Promotes Transforming Growth Factor-β-Mediated Epithelial-Mesenchymal Transition’, J. Biol. Chem, vol. 289, no. 50, 2014, pp. 34,627–34,641. LuJ. ‘β-Galactoside α2,6-Sialyltranferase 1 Promotes Transforming Growth Factor-β-Mediated Epithelial-Mesenchymal Transition’ J. Biol. Chem 289 50 2014 34,627 34,641 10.1074/jbc.M114.593392426386925344606 Search in Google Scholar

[33] Zhou, X. et al., ‘Sialidase NEU1 Suppresses Progression of Human Bladder Cancer Cells by Inhibiting Fibronectin-Integrin α5β1 Interaction and Akt Signaling Pathway’, Cell Commun. Signal, vol. 18, no. 1, 2020, p. 44. ZhouX ‘Sialidase NEU1 Suppresses Progression of Human Bladder Cancer Cells by Inhibiting Fibronectin-Integrin α5β1 Interaction and Akt Signaling Pathway’ Cell Commun. Signal 18 1 2020 44 10.1186/s12964-019-0500-x706684732164705 Search in Google Scholar

[34] Yamanami, H. et al., ‘Down-Regulation of Sialidase NEU4 May Contribute to Invasive Properties of Human Colon Cancers’, Cancer Sci, vol. 98, no. 3, 2007, pp. 299–307. YamanamiH ‘Down-Regulation of Sialidase NEU4 May Contribute to Invasive Properties of Human Colon Cancers’ Cancer Sci 98 3 2007 299 307 10.1111/j.1349-7006.2007.00403.x17270019 Search in Google Scholar

[35] Roncati, L, Barbolini, G, Gatti, AM, Pusiol, T, Piscioli, F, Maiorana, A., ‘The Uncontrolled Sialylation Is Related to Chemoresistant Metastatic Breast Cancer’, Pathol. Oncol. Res., vol. 22, no. 4, 2016, pp. 869–873. RoncatiL BarboliniG GattiAM PusiolT PiscioliF MaioranaA ‘The Uncontrolled Sialylation Is Related to Chemoresistant Metastatic Breast Cancer’ Pathol. Oncol. Res 22 4 2016 869 873 10.1007/s12253-016-0057-627037559 Search in Google Scholar

[36] Yen HY. et al. ‘Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition’ Proc. Natl. Acad. Sci. U. S. A., vol. 112, no. 22, 2015, pp. 6,955–6,960. YenHY ‘Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition’ Proc. Natl. Acad. Sci. U. S. A. 112 22 2015 6,955 6,960 10.1073/pnas.1507329112446051325971727 Search in Google Scholar

[37] Li, Y, Luo, S, Dong, W, Song, X, Zhou, H, Zhao, L, Jia, L, ‘Alpha-2, 3-Sialyltransferases Regulate the Multidrug Resistance of Chronic Myeloid Leukemia Through miR-4701-5p Targeting ST3GAL1’, Lab. Investig, vol. 96, no. 7, 2016, pp. 731–740. LiY LuoS DongW SongX ZhouH ZhaoL JiaL ‘Alpha-2, 3-Sialyltransferases Regulate the Multidrug Resistance of Chronic Myeloid Leukemia Through miR-4701-5p Targeting ST3GAL1’ Lab. Investig 96 7 2016 731 740 10.1038/labinvest.2016.5027088512 Search in Google Scholar

[38] Britain, CM, Holdbrooks, AT, Anderson, JC, Willey, C.D., and Bellis, S.L., ‘Sialylation of EGFR by the ST6Gal-I Sialyltransferase Promotes EGFR Activation and Resistance to Gefitinib-Mediated Cell Death’, J. Ovarian Res, vol. 11, no. 12, p.12. BritainCM HoldbrooksAT AndersonJC WilleyC.D. BellisS.L. ‘Sialylation of EGFR by the ST6Gal-I Sialyltransferase Promotes EGFR Activation and Resistance to Gefitinib-Mediated Cell Death’ J. Ovarian Res 11 12 12 10.1186/s13048-018-0385-0580001029402301 Search in Google Scholar

[39] Büll, C. et al., ‘Targeting Aberrant Sialylation in Cancer Cells Using a Fluorinated Sialic Acid Analog Impairs Adhesion, Migration, and In Vivo Tumor Growth’, Mol. Cancer Ther, vol. 12, no. 10, 2013, pp.1,935–1,946. BüllC ‘Targeting Aberrant Sialylation in Cancer Cells Using a Fluorinated Sialic Acid Analog Impairs Adhesion, Migration, and In Vivo Tumor Growth’ Mol. Cancer Ther 12 10 2013 1,935 1,946 10.1158/1535-7163.MCT-13-027923974695 Search in Google Scholar

[40] Sharma, P, Allison, JP, ‘Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential’, Cell, vol. 161, no. 2, 2015, pp. 205–214. SharmaP AllisonJP ‘Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential’ Cell 161 2 2015 205 214 10.1016/j.cell.2015.03.030590567425860605 Search in Google Scholar

[41] King, T, Posey, AD, ‘Co-Expression of an Engineered Cell-Surface Sialidase by CART Cells Improves Anti-Cancer Activity of NK Cells in Solid Tumors’, Cytotherapy, vol. 21, no. 5, 2019, p. S27. KingT PoseyAD ‘Co-Expression of an Engineered Cell-Surface Sialidase by CART Cells Improves Anti-Cancer Activity of NK Cells in Solid Tumors’ Cytotherapy 21 5 2019 S27 10.1016/j.jcyt.2019.03.338 Search in Google Scholar

[42] Dusoswa, SA. et al., ‘Glycan Modification of Glioblastoma-Derived Extracellular Vesicles Enhances Receptor-Mediated Targeting of Dendritic Cells’, J. Extracell. Vesicles, vol. 8, no. 1, 2019, p. 1,648,995. DusoswaSA ‘Glycan Modification of Glioblastoma-Derived Extracellular Vesicles Enhances Receptor-Mediated Targeting of Dendritic Cells’ J. Extracell. Vesicles 8 1 2019 1,648,995 10.1080/20013078.2019.1648995671314931489145 Search in Google Scholar

[43] Wang J., et al., ‘Siglec-15 as an Immune Suppressor and Potential Target for Normalization Cancer Immunotherapy’, Nat. Med, vol. 25, no. 4, 2019, pp. 656–666. WangJ. ‘Siglec-15 as an Immune Suppressor and Potential Target for Normalization Cancer Immunotherapy’ Nat. Med 25 4 2019 656 666 10.1038/s41591-019-0374-x717592030833750 Search in Google Scholar